BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353]
URL: https://www.wjgnet.com/1007-9327/full/v26/i3/353.htm
Number Citing Articles
1
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner, Marc S Ernstoff. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJournal for ImmunoTherapy of Cancer 2021; 9(6): e002435 doi: 10.1136/jitc-2021-002435
2
Marie-Léa Gauci, Barouyr Baroudjian, Celeste Lebbe, Olivier Roux. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case reportJournal for ImmunoTherapy of Cancer 2021; 9(3): e002337 doi: 10.1136/jitc-2021-002337
3
Sam Talbot, Vivienne MacLaren, Heather Lafferty. Sclerosing cholangitis in a patient treated with nivolumabBMJ Case Reports 2021; 14(5): e241700 doi: 10.1136/bcr-2021-241700
4
Masaki Takinami, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Yoshio Kiyohara, Hirofumi Yasui, Masashi Niwakawa, Toshiaki Takahashi. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitisInvestigational New Drugs 2021; 39(6): 1716 doi: 10.1007/s10637-021-01136-z
5
Einar S. Björnsson, Raul J. Andrade. Long-term sequelae of drug-induced liver injuryJournal of Hepatology 2021;  doi: 10.1016/j.jhep.2021.10.011
6
Kenji Urakabe, Takashi Mizushima, Hironobu Tsukamoto, Yasuaki Fujita, Kenichi Haneda, Yuta Suzuki, Akihisa Minowa, Ryo Ishihara, Yusuke Kito, Kazuko Watanabe, Fumihiro Okumura. Two cases of steroid-resistant nivolumab-induced sclerosing cholangitisKanzo 2021; 62(11): 712 doi: 10.2957/kanzo.62.712
7
Yuki Yoshikawa, Michio Imamura, Kenji Yamaoka, Yumi Kosaka, Eisuke Murakami, Kei Morio, Hatsue Fujino, Takashi Nakahara, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Clair Nelson Hayes, Hiroshi Aikata, Kazunori Fujitaka, Kouji Arihiro, Noboru Hattori, Kazuaki Chayama. A case with life-threatening secondary sclerosing cholangitis caused by nivolumabClinical Journal of Gastroenterology 2021; 14(1): 283 doi: 10.1007/s12328-020-01287-1
8
Joseph William Clinton, Sara Kiparizoska, Soorya Aggarwal, Stephanie Woo, William Davis, James H. Lewis. Drug-Induced Liver Injury: Highlights and Controversies in the Recent LiteratureDrug Safety 2021; 44(11): 1125 doi: 10.1007/s40264-021-01109-4
9
Emanuel Raschi, Milo Gatti, Francesco Gelsomino, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from PharmacovigilanceTargeted Oncology 2020; 15(4): 449 doi: 10.1007/s11523-020-00738-6
10
致文 沈. The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint InhibitorsAdvances in Clinical Medicine 2021; 11(10): 4628 doi: 10.12677/ACM.2021.1110680
11
Mauro Cataldi, Federica Manco, Giovanni Tarantino. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate StoryInternational Journal of Molecular Sciences 2021; 22(23): 12947 doi: 10.3390/ijms222312947
12
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang. <p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>Drug Design, Development and Therapy 2020; : 3625 doi: 10.2147/DDDT.S267433
13
Kentaro Sato, Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Atsushi Takahashi, Hiromasa Ohira. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case reportClinical Journal of Gastroenterology 2020; 13(6): 1310 doi: 10.1007/s12328-020-01178-5
14
Sachiko Matsumoto, Keisuke Watanabe, Nobuaki Kobayashi, Kuniyasu Irie, Shoji Yamanaka, Takeshi Kaneko. Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patientRespirology Case Reports 2020; 8(5) doi: 10.1002/rcr2.560
15
Ryunosuke Ooi, Kazunori Tobino, Mitsukuni Sakabe, Takafumi Kawabata, Yuri Hiramatsu, Takuto Sueyasu, Kohei Yoshimine. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitisRespiratory Medicine Case Reports 2020; 31: 101197 doi: 10.1016/j.rmcr.2020.101197
16
Dimitrios C Ziogas, Helen Gogas. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et alJournal for ImmunoTherapy of Cancer 2021; 9(3): e002391 doi: 10.1136/jitc-2021-002391
17
Shinji Nabeshima, Masahiro Yamasaki, Naoko Matsumoto, Shintaro Takaki, Yumi Nishi, Kazuma Kawamoto, Masaya Taniwaki, Nobuyuki Ohashi, Noboru Hattori. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case reportCancer Treatment and Research Communications 2021; 26: 100270 doi: 10.1016/j.ctarc.2020.100270
18
Johanna Winter, Max M. Lenders, Maximilian Gassenmaier, Andrea Forschner, Ulrike Leiter, Benjamin Weide, Mette-Triin Purde, Lukas Flatz, Antonio Cozzio, Martin Röcken, Claus Garbe, Thomas K. Eigentler, Nikolaus B. Wagner. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitorsCancer Immunology, Immunotherapy 2021; 70(4): 1089 doi: 10.1007/s00262-020-02768-5
19
Tess McClure, Wanyuan Cui, Khashayar Asadi, Thomas John, Adam Testro. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-upBMJ Open Gastroenterology 2020; 7(1): e000487 doi: 10.1136/bmjgast-2020-000487